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 Red blood cell (RBC) transfusion is common in critically ill, post-surgical, and post-
trauma patients in whom both systemic inflammation and immune suppression are associated 
with adverse outcomes.  RBC products contain a multitude of immunomodulatory mediators that 
interact with and alter immune cell function.  These interactions can lead to both pro-
inflammatory and immunosuppressive effects.  Defining clinical outcomes related to 
immunomodulatory effects of RBCs in transfused patients remains a challenge, likely due to 
complex interactions between individual blood product characteristics and patient-specific risk 
factors.  Unpacking these complexities requires an in depth understanding of the mechanisms of 
immunomodulatory effects of RBC products.  In this review, we outline and classify potential 
mediators of RBC transfusion-related immunomodulation and provide suggestions for future 
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 In the United States, 11 to 16 million red blood cell (RBC) units were administered 
annually during the last decade, equating to a RBC transfusion every 2 seconds.
1-5
   RBC 
transfusion is particularly commonplace in emergency departments, intensive care units (ICUs) 
and operating suites, with 37-60% of ICU patients receiving a transfusion during 
hospitalization.
6-12
   Nonetheless, RBC transfusion may have deleterious immunologic effects, 
particularly for critically ill patients.
13,14
  Mounting evidence from predominantly observational 
studies demonstrate independent associations between RBC transfusion, dysregulated immunity 
and increased mortality and morbidity; mechanisms of which are only partly understood.
15-26
  
The following review will summarize current literature on mechanisms of RBC transfusion-
related immunomodulation, classify potential mediators, and propose a research agenda to fill 
critical knowledge. 
Red Blood Cell Transfusion-Related Immunomodulation 
Beginning in 1973, Opelz and colleagues provided initial evidence for RBC transfusion-
related immunomodulation (TRIM) with the observation that the survival rate of transplanted 
kidneys was significantly higher in cadaveric renal transplant patients who received RBC 
transfusion.
13,27
   These findings strongly suggested immunosuppressive effects of non-
leukoreduced allogeneic RBC transfusion.  More recent findings suggest both pro-inflammatory 
and immunosuppressive effects of RBC product exposure, including pre-storage leukoreduced 
blood products.  Clinically, RBC transfusion is associated with new or worsening organ 
dysfunction, the development of nosocomial infection, and cancer recurrence, suggesting 
dysregulated recipient immune responses.
13,14,21,28-32
  The extent to which RBC transfusion 
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tdirectly contributes to immunologic dysregulation in transfused patients remains unclear, though 
a wealth of pre-clinical evidence demonstrates that RBC products can directly modulate immune 
cell function.  In a variety of pre-clinical models, RBC product exposure results in inflammatory 
effects including: leukocyte priming, enhanced neutrophil chemotaxis, monocyte/macrophage 
activation, and inflammatory cytokine release.
13,17,21,31,33-35
  Immunosuppressive effects include 
impaired natural killer cell function, alterations in T lymphocyte ratios, defective antigen 
presentation, suppression of lymphocyte proliferation, and decreased macrophage phagocytic 
function.
14,36-40
   While evidence supporting both pro-inflammatory and immunosuppressive 
effects of RBC transfusion may seem contradictory, given the complex nature of transfused 
blood products and the multitude of potentially immunomodulatory mediators contained therein, 
mixed effects are not  surprising.  Indeed, mixed immunomodulatory potential of RBC 
transfusion may be particularly relevant for critically ill patients in whom both excess 
inflammation and immune suppression are significantly associated with adverse outcomes.
14
  
Overall, defining the sum total immunomodulatory effects of particular RBC products in 
individual patients remains challenging.  Future research to determine the effects of individual 
blood products on individual patients and to mitigate potential risks depends on understanding 
mechanisms of RBC transfusion-related immunomodulation.   
While mechanisms for RBC transfusion-related immunomodulation are not yet fully 
characterized, many potential mediators have been identified.   These include leukocyte-derived 
mediators, component hemolytic contents (heme, iron release), platelet-derived factors, and 
extracellular vesicles (Figure 1).   
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1.  Leukocytes and Leukocyte-derived Mediators  
The observation that pre-storage leukoreduction may mitigate TRIM suggests that either 
intact leukocytes and/or soluble leukocyte-derived mediators play a role in its development.
41-44
 
Leukoreduction removes most residual white blood cells from stored blood components and 
appears to improve clinical outcomes.  Randomized trials in surgical patients receiving either 
leukoreduced versus non-leukoreduced RBCs, autologous versus allogeneic RBC transfusions, 
or restrictive versus liberal RBC transfusion thresholds demonstrate that in each case, subjects in 
the leukoreduced, autologous or restricted transfusion arms developed fewer nosocomial 
infections.
15,45-47
  Likewise, meta-analyses demonstrate that leukoreduction, autologous RBC 
transfusions (which prevent exposure to allogeneic WBCs) and restrictive transfusion thresholds 
(which decrease exposure to residual allogeneic WBCs) are each associated with decreased risk 
of post-operative infection.
15,45,47
  RBC unit leukoreduction may also attenuate the systemic 
inflammatory response following cardiac surgery, with a dose-dependent increase in survival 
when leukoreduced RBCs are utilized.
48
  Lastly, animal models demonstrate that leukoreduction 
may reduce transfusion-associated cancer metastasis and T cell apoptosis.
29,49
  Taken together, 
these data suggest that residual leukocytes or leukocyte-derived mediators in RBC products may 
be harmful via immunomodulatory mechanisms.  Although in the US, 75-80% of RBC units 
transfused are pre-storage leukoreduced to  mitigate these risks, it is worth noting that a 
substantial number of residual leukocytes (~5000 to ~ 5 x 10
6
 leukocytes/unit) remain despite 
current leukoreduction technologies.
50-52
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  Antigen presenting cells (i.e. monocytes and dendritic cells) carry major-
histocompatibility complex (MHC) II molecules (i.e. HLA-DR) on their cell surfaces.  MHC II 
molecules function to present processed antigens and activate lymphocytes.  Following 
transfusion, interactions between donor MHC II molecules on residual leukocytes and recipient 
lymphocytes may result in either alloimmunization or immune suppression.
53-56
  Features such as 
the degree of HLA compatibility, the functionality of donor antigen presenting cells (APCs), and 
the inflammatory state of the recipient likely determine whether residual allogeneic leukocytes 
induce imm ne tolerance or alloimmunization.
21
  In the case of immune suppression, residual 
allogeneic APCs which engage recipient T cells without necessary secondary or co-stimulatory 
signals would be expected to produce antigen-specific T cell anergy.
21
  The resulting immune 
tolerance is  proposed mechanism for allogenic RBC transfusion-related adaptive immune cell 
(T cell) suppression.
21
  T cell immune tolerance may also be responsible for development of 
microchimerism in allogenic blood transfusion recipients, whereby donor leukocytes fail to elicit 
an immune response and become “accepted” by the recipient.
57
  Microchimerism may be 
common in trauma patients and may persist for up to two years following transfusion.
57,58
  
Moreover, immune tolerance and associated microchimerism may explain the observed shift to 
immunosuppressive TH2 responses following blood transfusion.
38,59-62
  However, clear 
demonstration of direct causal links between HLA molecules on residual allogeneic APCs and 
post-transfusion immune suppression is currently lacking.    
 In addition to residual functional allogeneic leukocytes, it is possible that apoptotic 
leukocytes in RBC products may also induce immune suppression.
63
 During collection and 
storage, leukocytes undergo apoptosis.
64
  One of the early steps in apoptosis involves exposure of 
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tphosphatidyl serine on the outer leaflet of the cell membrane.  Interaction between immune cells 
and phosphatidyl serine has been shown to induce immunosuppressive signals, including release 
of anti-inflammatory cytokines IL-10 and TGF-β, inhibition of pro-inflammatory cytokine 
release, inhibition of APC activation, and predominance of immunosuppressive regulatory T 
cells.
63,65
  The degree to which apoptotic residual leukocytes in RBC units contribute to recipient 
immune suppression in the clinical setting remains unknown.  However, it is worth noting that 
similar responses may also be seen in response to phosphatidyl serine-containing membrane 
fragments or microparticles.   
 
Soluble leukocyte-derived mediators 
Removal of supernatant from stored RBC units by washing reduces the inflammatory 
response in pediatric cardiac surgery patients and pre-clinical studies suggest that RBC-induced 
immunomodulation can be recapitulated using RBC unit supernatants.
24,25,66,67
  Thus, it seems 
likely that soluble mediators also play a role in TRIM pathogenesis.     
There are multiple soluble leukocyte-derived factors, including cytokines, white blood 
cell degranulation products, soluble FAS-L, and soluble HLA molecules, which directly inhibit 
the immune response.
68,69
 Of these, sFAS-L and the anti-inflammatory cytokine, TGFβ have the 
strongest evidence suggesting that they may promote TRIM, particularly in non-leukoreduced 
blood products.
36,68
  In vitro studies indicate that sFAS-L and TGFβ found in blood components 
may directly induce innate immune cell apoptosis, impair neutrophil chemotaxis, and decrease 
natural killer cell activity.
36,69,70
  Immunosuppressive effects may not be limited to these, as 
TGFβ is a known anti-inflammatory cytokine with broad immunosuppressive effects. 
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tIn addition to anti-inflammatory cytokines, pro-inflammatory cytokines may also 
accumulate in blood products during storage.
71-74
  However, in some reports pre-storage 
leukoreduction appears to substantially decrease the accumulation of pro-inflammatory cytokines 
in RBC products such that levels are undetectable.
72,74
  When cytokines are detected, it is unclear 
whether their concentrations are high enough to strongly influence recipient immune 
function.
73,74
  In addition to cytokines, white blood cell degranulation products such as histamine 
and eosinophil cationic protein have been detected in red blood cell components.
75
  Each of these 
mediators has immunomodulatory potential.  For example, histamine has been shown to inhibit 
neutrophil chemotaxis and decrease T cell proliferation, while eosinophilic cationic protein may 
also reduce T cell proliferation.
76,77
       
 While leukocytes and leukocyte-derived soluble mediators appear to promote TRIM, 
such effects are likely reduced by pre-storage leukoreduction.  Because evidence for TRIM 
remains in the post-leukoreduction era, it is likely that non-WBC derived factors are also 
involved.
14
   
 
2.  Red Blood Cell Storage Lesion and Decompartmentalized RBC Contents  
 Another potential mechanism for TRIM arises from the RBC, itself.  As RBC units age 
under refrigerated conditions, a well described “storage lesion(s)” develops.  The RBC storage 
lesions are characterized by altered RBC morphology, rheological changes, metabolic 
derangements, changes in oxygen affinity, changes in osmotic regulation, and changes in the 
ability to vasoregulate.
78-85
 In addition, RBC hemolysis (both during storage and post-
transfusion) can lead to reduced pH, increased lactate and other metabolic wastes, release of 
microparticles, as well as accumulation of cell-free hemoglobin (CFH), heme, and iron.
26,78,86-90
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tIron content can be in the form of transferrin bound iron (TBI), non- transferrin bound iron 
(NTBI), or plasma labile iron (PLI).  Given the well-described bioactivities of these species, 
RBC hemolysis can disturb plasma redox balance and broadly disrupt normal signaling in 
coagulation, vascular, and immune systems.
4,22,23,78,86,91,92
    
In normal physiology, plasma haptoglobin sequesters CFH, forming a complex for 
removal by macrophages via CD163.
18,22,23,93
   However in critical illness, even moderate 
intravascular hemolysis may overwhelm plasma-binding capacity resulting in unbound 
extracellular hemoglobin.  When extracellular hemoglobin is unbound, it becomes oxidized to 
methemoglobin, releasing free heme.  Free heme can then undergo the Fenton Reaction to cause 
further release of iron..
67,93-97
   Accumulation of un-complexed heme and iron in plasma is 
associated with significant tissue damage, presumably by iron-catalyzed generation of reactive 
oxygen species (ROS), promotion of other radical chains, increases in leukocyte activation and 
migration, upregulation of adhesion molecules, and subsequent deleterious effects to tissue 
barriers and to immunity.
22,93,98-104
  In murine models, transfusion of long-stored RBCs led to 
increased iron in the form of NTBI and augmented circulating pro-inflammatory cytokine 
release.
22,23,105,106
   However, in human healthy volunteers, while transfusion with older versus 
fresher RBCs significantly increased circulating NTBI levels, a pro-inflammatory cytokine 
response was not observed. 
91,105,107
  The lack of observed inflammatory response in the human 
studies may relate to differences between mice and humans, relative transfusion dose; or the 
inflammatory response to RBC transfusion may not be apparent in healthy subjects (without 
underlying inflammation).  That said, in a study of 33 premature neonates, while levels of NTBI 
were increased post transfusion, NTBI levels were not associated with increases in plasma 
Page 9 of 27
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901 1 (434) 964-4100
Transfusion









tinflammatory cytokines.108  These data suggest that pro-inflammatory effects of NTBI may be 
minimal.   
 RBC transfusion may also burden the mononuclear phagocyte system (MPS), delivering 
large amounts of hemoglobin and RBC contents to monocytes and macrophages.
93
  Phagocytosis 
of RBCs by macrophages (i.e. extravascular hemolysis) increases macrophage intracellular heme 
and iron to a degree that can trigger inflammasome activation and pro-inflammatory cytokine 
release via NLRP3 and NF-κB signaling; this process is further exacerbated by generation of 
iron-related reactive oxygen species.
93
 Conversely, macrophage exposure to high concentrations 
of heme may also bias macrophage phenotype from the activated/inflammatory (M1) phenotype 
toward an immunosuppressive (M2) profile via upregulation of heme-oxygenase 1 and release of 
the anti-inflammatory cytokine, IL-10.
109
  Similarly, macrophage iron loading may promote 
immune suppression by inhibiting IFN-γ-mediated secretion of pro-inflammatory cytokines, 
reducing expression of MHC II and impairing nitric oxide synthesis.  Cumulatively, these effects 
compromise phagocytic and microbicidal macrophage activity.
110
  Iron overload may also further 
promote immune suppression by impairing proliferation and activation of T, B, and natural killer 
cells.
111
  Additionally, independent of direct effects on immune cells, un-complexed heme and 
iron may directly promote bacterial growth.
78,93,105
   
 Finally, an additional compound of interest is ubiquitin, an intracellular regulatory 
protein present in a variety of cell types.  RBCs carry large amounts of ubiquitin relative to other 
cell types, and extracellular ubiquitin has been found to accumulate in RBC unit supernatants 
during storage.
112
  Extracellular ubiquitin has varied effects on immune cell function, including 
blunting LPS-induced TNFα production while augmenting LPS-induced IL-8 production.
112-114
 
Additionally, extracellular ubiquitin found in RBC units may skew helper T cell function toward 
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tan immunosuppressive Th2 phenotype, as evidenced by increased IL-4 production and decreased 
IFNγ production by LPS-stimulated PBMCs exposed to 35-day-old stored RBC supernatant or 
ubiquitin.
112,114
  The mix of pro-inflammatory and immunosuppressive effects of extracellular 
ubiquitin mirrors immunomodulatory effects observed in response to RBC supernatants in vitro 
and may explain mixed responses reported in vivo. 
In summary, soluble mediators resulting from RBC ageing and breakdown are varied, 
and individual mediators likely have pleiotropic effects on recipient immune response.  Although 
animal studies show worsened survival and increased inflammation from transfusion with longer 
stored RBCs, these findings have not been demonstrated in recently published human 
RCTs
4,16,78,87,115
.  This may be because animals studies can carefully delineate “fresh vs. old” 
RBC cutoffs (i.e. >21 days) whichhas proven difficult in human RCTs, where a mean duration of 
RBC storage in the US of 17.9 days results in comparisons between “fresh” vs. “middle-
age”
87,116
.    Additionally, storage duration effects may be more robust if transfusion occurs in the 
setting of more significant baseline inflammation, though to date this question has not been 
adequately evaluated.  The relative impact of inflammatory and immunosuppressive effects of 
RBC-derived mediators for individual patients, particularly in the setting of baseline 
inflammation or immune suppression, remains largely unknown.  It is likely that a complex 
interplay between de-compartmentalized RBC contents and underlying host immune response 
contributes to patient-specific immune modulation, a topic of active ongoing research.    
   
3.  Residual Platelets and Platelet-derived Factors 
 While less is known about platelet-derived factors as TRIM mediators, emerging data 
strongly suggests that platelets and platelet-derived factors have important immunomodulatory 
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tpotential.117-119  For instance, platelet-derived microparticles are capable of inducing both 
immune cell suppression and activation.
120,121
  Platelets themselves may play important roles in 
modulating immune cell response in both health and disease, suggesting that residual platelets 
found in RBC products likely contribute to immunomodulation.  Non-leukocyte reduced RBC 
units have been shown to accumulate platelet-leukocyte aggregates over time, which correlate 
with immune cell apoptosis and monocyte tissue factor expression.
122
  These changes are 
expected to be immunomodulatory, however effects of platelet-leukocyte aggregates on recipient 
immune cells was not evaluated.  Likewise, the immunodulatory potential of residual platelets 
within leukoreduced red blood cell products is unknown.   
 
4.  Bioactive Lipids and Extracellular Vesicles  
Bioactive Lipids 
Bioactive lipids with pro-inflammatory and pro-coagulant activity accumulate during 
storage in RBC units and may contribute to inflammatory complications of RBC transfusion, 
including transfusion-related acute lung injury (TRALI).
83,123
 Accumulation of some bioactive 
lipids, such as lysophosphatidylcholines, appears to be reduced by leukoreduction.
124
 However, a 
variety of polyunsaturated fatty acids, including arachidonic acid, linoleic acid, docosahexaenoic 
acid, and their metabolites accumulate in RBC units despite leukoreduction.
123,125
  Arachidonic 
acid and its oxidized metabolites, when isolated from older stored RBC supernatants, are capable 
of priming neutrophils in vitro.  Further, infusion of these bioactive lipids in rats that are primed 
by LPS, induce acute lung injury - providing evidence that bioactive lipids may provide the 
second-hit in the two-hit model of non-antibody mediated TRALI.
125,126
  Observational studies 
demonstrating the presence of lipids with neutrophil priming activity in the plasma of TRALI 
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tpatients provide additional supportive evidence of the link between bioactive lipids and non-
antibody mediated TRALI.
127
  The extent to which bioactive lipids may contribute to systemic 
inflammation or modulation of immune function outside of TRALI remains unclear and is a 




Extracellular vesicle count and profile in blood products 
 The term extracellular vesicle (EV) broadly encompasses larger microvesicles (200-1200 
nm), exosomes (30-150 nm) and apoptotic bodies (50-500 nm).
128-130
  For over a decade, it has 
been appreciated that plasma from healthy subjects contains EVs, including exosomes, derived 
from leukocytes, platelets, RBCs and endothelial cells.
131-133
   
 EV counts in RBC products increase with storage duration.
86,134
  Storage-related 
morphological changes to RBCs are accompanied by shedding and release of RBC-derived EVs, 
while residual platelets and leukocytes contribute to platelet-derived and leukocyte-derived 
EVs.
135-138
  Tracking EV cell of origin reveals that RBC-derived EVs increase continuously 
during storage, while platelet-derived EV counts peak at 3-4 weeks of storage.
86,139
  EV release 
and accumulation are significantly influenced by component manufacture processes and storage 




In vitro evidence for EV TRIM effects 
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t Though once considered debris without bioactivity and discounted as artifact, EVs are 
increasingly recognized as playing a central role in the body’s complex network of intercellular 
signaling, both in normal physiology and in disease.
142
  EVs derived from stored platelets bind to 





  Neutrophil and RBC-derived EVs are also capable of 
suppressing inflammatory responses.
130,145
  Similar to the variability in effects of EVs from 
various cell types, EVs isolated from plasma have dual pro-inflammatory and 
immunosuppressive effects.
139,146
  The proposed mechanism of action of blood-derived EVs 
varies, with immunosuppressive effects potentially mediated by FasL expression by EVs, and 
inflammatory effects resulting from direct activation of monocytes and other antigen-presenting 
cells after EV uptake by these cells.
139,146
  
In vivo evidence for EV TRIM effects 
 Given the incomplete understanding of how EVs from different cells of origin might act, 
it is not surprising that in vivo evidence of an EV-based role in TRIM is scant.  The circulating 
half-life of EVs appears to be fairly short, less than 15-20 minutes in a rat model.
86
  However, 
the biologic activity of EVs is likely related to EV uptake by target cells rather than plasma 
concentration.  For example, injected EVs are rapidly and widely distributed to the spleen, liver, 
kidneys, and lungs in mice.
147
  Donor dendritic cell-derived EV uptake by dendritic cells in a 
recipient mouse can activate responding T cells in an antigen-specific manner.
148
  This property 
has been exploited by several groups as a potential vaccine delivery approach.
149-151
  
Additionally, adoptive transfer of CD154 (CD40L)-expressing platelet-derived EVs is sufficient 
to stimulate IgG production and germinal center formation in mice after adenovirus vaccination, 
indicating that exogenous EVs can modulate a nascent immune response
152
.  The significance of 
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tthe immunomodulatory effects of EVs found in blood products transfusion recipients remains an 
open question and an area of active research.  Better understanding EV interaction with the 
human immune system would allow manipulation of this pathway, both in the context of 




 Ample evidence exists that RBC products are capable of interacting with and modulating 
immune cell function through a variety of mechanisms and mediators; however, conclusive 
clinical evidence of TRIM effects in transfused patients remains elusive.  Given recent clinical 
studies that fail to demonstrate benefit to fresh RBC transfusion compared to longer stored 
products, one might conclude that RBC TRIM does not exist in the era of pre-storage 
leukoreduced blood products or that RBC storage duration does not contribute to TRIM 
mechanisms.
87,115,153,154
  However, emerging evidence suggests that the concentrations of 
potentially immunomodulatory mediators vary not only with storage duration, but also with 
donor characteristics, manufacturer, storage solution, and other processing factors.
88,155-158
   We 
are only beginning to understand the complex interplay between storage duration, processing 
methods, RBC unit contents, and subsequent potential TRIM effects.  Similarly, a patient’s 
underlying state of inflammation and/or immune suppression at the time of transfusion likely 
influences the immunologic response to transfusion.  Critically ill patients, in particular, exhibit 
both exaggerated systemic inflammation and immune suppression that fluctuate over time.
159-164
  
In this context, one would expect that immunologic effects of RBC transfusion might vary 
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twidely based on the underlying state of the recipient’s immunologic response.  However, most 
studies to date have failed to sufficiently characterize or account for individual differences in 
pre-transfusion immune function.  Additionally, patients who are transfused with RBCs often 
also receive other blood products, which may have different or additive TRIM effects.
14,165
    
Overall, much work remains to understand interactions between individual blood product 
characteristi s and patient-specific risk factors with respect to clinical consequences of TRIM.   
Defining immunomodulatory mediators found within blood products, and understanding 
how these mediators may modulate recipient immunity is essential to identify potential TRIM 
effects at the bedside.  A bench to bedside approach must carefully attempt to define these 
mediators in context of host immune function.  Next, guided by an enhanced understanding of 
TRIM biology, observational studies will be necessary to determine patient-specific risk factors 
for specific TRIM effects and related clinical consequences.  Moreover, delineation of the effects 
of RBC donor, product processing and storage conditions upon accumulation of 
immunomodulatory mediators can then inform future prospective and interventional trials aimed 
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Red blood cell (RBC) units contain multiple immunomodulatory mediators, including 
leukocyte-derived, red blood cell-derived, platelet-derived, and lipid and microvesicle-
derived factors.  Effects of these mediators on immune cell function vary and include both 
inflammatory and immunosuppressive changes.  As such, the sum total 
immunomodulatory effects of RBC transfusion on recipient immune function will likely 
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